| Please review the responses below in perspective with
medications that have been approved by the FDA
for migraine prevention. For example, in a study
to observe the long
term efficacy of Depakote
for migraine prevention, only 5% had continued to use Depakote for as
long as 3 years, and reported an average 66% reduction of migraine
events, while 70% continue to use an NTI with excellent results. |
Chart from
the Depakote study: |
back to NTI-tss mainpage